Inovio Pharmaceuticals, Inc. (INO) Stock Price & Analysis
Inovio Pharmaceuticals, Inc. (INO) fell 4.89% to USD 0.97 as of July 25, 2026 at 02:25 UTC, according to Nexqual real-time market data.
INO last closed at USD 1.02; the session ranged USD 0.96–1.04 on volume of 3,656,389 shares. Market capitalization is —, with a 52-week range of USD 0.96–2.98 (NCM). Source: Nexqual, July 25, 2026 at 02:25 UTC.
Key Statistics (as of July 25, 2026 at 02:25 UTC)
| Price | USD 0.97 |
|---|---|
| Change | ▼ 4.89% (down) |
| Previous Close | USD 1.02 |
| Open | USD 1.04 |
| Day Range | USD 0.96 – 1.04 |
| 52-Week Range | USD 0.96 – 2.98 |
| Volume | 3,656,389 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (INO)
Nexqual's technical model rates INO "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.11 (oversold) |
| vs SMA50 | Below (USD 1.17) |
| MACD | -0.03 (negative) |
Analyst Ratings (INO)
Wall Street analysts rate INO "Hold" based on 3 analysts, with a mean price target of USD 3.43 (range USD 1.8–6), per Nexqual as of July 25, 2026 at 02:25 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.43 |
| High Target | USD 6 |
| Low Target | USD 1.8 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (INO)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.31 vs est -0.33 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.35 ▲ beat |
| 2025-09-30 | USD -0.87 vs est -0.48 ▼ miss |
| 2025-06-30 | USD -0.61 vs est -0.62 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:25 UTC.
Financials & Fundamentals (INO)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -296.36% |
| Debt / Equity | 143.3 |
| Current Ratio | 1.04 |
| Total Cash | $37.68M |
| Total Debt | $8.70M |
| Free Cash Flow | $-34.47M |
Source: Nexqual, July 25, 2026 at 02:25 UTC.
Financial Health Score (INO)
Nexqual rates Inovio Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 02:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $38M cash vs $9M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$83M |
| Efficiency | Critical — ROE -296%, ROA -76.4% |
Ownership (INO)
| Insider Ownership | +0.42% |
|---|---|
| Institutional Ownership | +47.30% |
| Float | 81.88M |
| Short % of Float | +20.87% |
Source: Nexqual, July 25, 2026 at 02:25 UTC.
Leadership (INO)
Inovio Pharmaceuticals, Inc. is led by Jacqueline E. Shea (age 59), CEO, President & Director, per Nexqual as of July 25, 2026 at 02:25 UTC.
| CEO, President & Director | Jacqueline E. Shea (age 59) |
|---|---|
| Chief Financial Officer | Peter D. Kies (age 62) |
| Chief Scientific Officer & Chairman of the Scientific Advisory Board | Laurent M. Humeau (age 58) |
| Director of Communications | Jennie Willson |
| Senior Vice President of Quality Assurance | E. J. Brandreth |
Major Backers & Investors (INO)
Notable institutional backers of Inovio Pharmaceuticals, Inc. include FMR, LLC, Fidelity, Janus Henderson Group PLC, according to Nexqual as of July 25, 2026 at 02:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 11.35% |
| Fidelity | 10.95% |
| Janus Henderson Group PLC | 4.02% |
| Boxer Capital Management, LLC | 2.88% |
| Shaw D.E. & Co., Inc. | 2.69% |
| Adar1 Capital Management, LLC | 1.79% |
| Millennium Management | 1.71% |
| Eversept Partners, LP | 1.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.96% |
Source: Nexqual, July 25, 2026 at 02:25 UTC.
From Inovio Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
- Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
- The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial.
- The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 3.13% |
| NVAX | Novavax, Inc. | USD 7.46 | ▼ 5.69% |
| SRNE | Sorrento Therapeutics, Inc. | USD 0 | ▲ 0% |
| MRNA | Moderna, Inc. | USD 54.07 | ▼ 6.89% |
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:25 UTC. This page is informational and not investment advice.